SCHEMBL7052149

SCHEMBL7052149

CC(C)CC(O)(C[PH2]=O)C(=O)OCSc1ccc2ccccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRNP P04156 8/20 0.46
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
RXFP1 Q9HBX9 5/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 5/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
NPSR1 Q6W5P4 4/20 0.41
MAPK10 P53779 2/20 0.41
RAB9A P51151 2/20 0.40
HPGD P15428 2/20 0.40
MAPT P10636 4/20 0.38
THRB P10828 1/20 0.36
LMNA P02545 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
NPC1 O15118 1/20 0.35
CYP1A2 P05177 1/20 0.34
PTBP1 P26599 1/20 0.34
KCNK2 O95069 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7445079 0.83 PRNP (0.47) PRNPKMT2AMEN1RXFP1KDM4E
SCHEMBL7445068 0.75 PRNP (0.48) PRNPKMT2AMEN1RXFP1KDM4E
SCHEMBL7052152 0.70 PRNP (0.47) PRNPKMT2AMEN1RXFP1KDM4E
SCHEMBL7050255 0.70 PRNP (0.47) PRNPKMT2AMEN1RXFP1KDM4E
SCHEMBL8764856 0.68 PRNP (0.53) PRNPKMT2AMEN1RXFP1KDM4E
SCHEMBL7434009 0.67 PRNP (0.44) PRNPKMT2AMEN1RXFP1KDM4E
SCHEMBL7049724 0.66 PRNP (0.50) PRNPKMT2AMEN1RXFP1KDM4E
SCHEMBL7449795 0.66 PRNP (0.53) PRNPKMT2AMEN1RXFP1KDM4E
SCHEMBL7048994 0.66 PRNP (0.51) PRNPKMT2AMEN1RXFP1KDM4E
SCHEMBL7445072 0.66 PRNP (0.50) PRNPKMT2AMEN1RXFP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
US-6013792-A INTERSTITIAL COLLAGENASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIOSTEOPOROSIS AGENTS SYNTEX (U.S.A.), INC. (US) 2000-01-11 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
WO-1996023791-A1 BRIDGED INDOLES AS MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-08-08 WO disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed
EP-0712403-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1996-05-22 EP disclosed
WO-1995004735-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1995-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 PRNP 327/4885KMT2A 4072/4885MEN1 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.